CRISPR and the Future of Cancer Treatments: Implications for Malaysian Medical Students
DOI:
https://doi.org/10.31674/mjmr.2026.v010i01.011Abstract
The emergence of CRISPR-Cas9 gene-editing technology has marked a transformative milestone in biomedical research, offering unprecedented potential to develop targeted therapies for a range of diseases, particularly cancer. This paper delves into the role of CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) in advancing cancer treatment, with an emphasis on the fundamental mechanisms of the technology, its promise for more precise and effective therapies, and the challenges encountered in translating CRISPR from the laboratory to clinical settings. The technology’s ability to precisely target and modify genes has the potential to revolutionize cancer therapies, offering personalized treatments tailored to the genetic makeup of individual tumors. However, the clinical application of CRISPR faces significant hurdles, including concerns about off-target effects, ethical dilemmas surrounding germline editing, and the development of safe and efficient delivery mechanisms. In the context of Malaysia, this paper explores the relevance of CRISPR innovation within the medical and educational sectors. It highlights how Malaysian medical schools are incorporating gene-editing technologies into curricula to ensure future healthcare professionals are well-prepared to navigate the complexities of CRISPR applications. Moreover, the discussion expands to include the ethical, social, and legal implications of CRISPR technology. Establishing robust national bioethical guidelines will be crucial in ensuring its responsible use and minimizing risks. The paper concludes by discussing the necessary infrastructure, educational advancements, and policy frameworks needed in Malaysia to facilitate the integration of CRISPR technology into cancer care, ensuring safe and effective treatment options for patients.
Keywords:
Biotechnology, Cancer Treatment, CRISPR-Cas9, Ethics in Genetics, Gene Editing, Malaysia, Medical Education, Precision MedicineDownloads
References
Alamillo, J. M., López, C. M., Rivas, F. J. M., Torralbo, F., Bulut, M., & Alseekh, S. (2023). Clustered regularly interspaced short palindromic repeats/CRISPR-associated protein and hairy roots: a perfect match for gene functional analysis and crop improvement. Current Opinion in Biotechnology, 79, 102876. https://doi.org/10.1016/j.copbio.2022.102876
Asmamaw, M., & Zawdie, B. (2021). Mechanism and applications of CRISPR/Cas-9-mediated genome editing. Biologics: Targets and Therapy, 353-361. https://doi.org/10.2147/BTT.S326422
Barbosa, S., Toe, L. P., Thizy, D., Vaz, M., & Carter, L. (2021). Engagement and social acceptance in genome editing for human benefit: Reflections on research and practice in a global context. Wellcome Open Research, 5, 244. https://doi.org/10.12688/wellcomeopenres.16260.2
Bender, G., Fahrioglu Yamaci, R., & Taneri, B. (2021). CRISPR and KRAS: a match yet to be made. Journal of biomedical science, 28(1), 77. https://doi.org/10.1186/s12929-021-00772-0
Geethakumari, P. R., Ramasamy, D. P., Dholaria, B., Berdeja, J., & Kansagra, A. (2021). Balancing quality, cost, and access during delivery of newer cellular and immunotherapy treatments. Current Hematologic Malignancy Reports, 16(4), 345-356. https://doi.org/10.1007/s11899-021-00635-3
Goetz, L. H., & Schork, N. J. (2018). Personalized medicine: motivation, challenges, and progress. Fertility and Sterility, 109(6), 952-963. https://doi.org/10.1016/j.fertnstert.2018.05.006
Hasbullah, H. H., & Musa, M. (2021). Gene therapy targeting p53 and KRAS for colorectal cancer treatment: a myth or the way forward?. International Journal of Molecular Sciences, 22(21), 11941. https://doi.org/10.3390/ijms222111941
Ho, P. J., Yeoh, Y. S., Miao, H., Lim, S. H., Tan, E. Y., Tan, B. K. T., ... & Hartman, M. (2021). Cohort profile: The Singapore Breast Cancer Cohort (SGBCC), a multi-center breast cancer cohort for evaluation of phenotypic risk factors and genetic markers. PLoS One, 16(4), e0250102. https://doi.org/10.1371/journal.pone.0250102
Isa, N. M., Zulkifli, N. A., & Man, S. (2020). Islamic perspectives on CRISPR/Cas9-mediated human germline gene editing: a preliminary discussion. Science and Engineering Ethics, 26(1), 309-323. https://doi.org/10.1007/s11948-019-00098-z
Jafri, W., & Kamran, M. (2019). Hepatocellular carcinoma in Asia: a challenging situation. Euroasian Journal of Hepato-Gastroenterology, 9(1), 27. https://doi.org/10.5005/jp-journals-10018-1292
Kalidasan, V., & Das, K. T. (2021). Is Malaysia ready for human gene editing: A regulatory, biosafety and biosecurity perspective. Frontiers in Bioengineering and Biotechnology, 9, 649203. https://doi.org/10.3389/fbioe.2021.649203
Kelly, M. M., Martin-Peters, T., & Farber, J. S. (2024). Secondary Data Analysis: Using existing data to answer new questions. Journal of Pediatric Health Care, 38(4), 615-618. https://doi.org/10.1016/j.pedhc.2024.03.005
Li, T., Li, S., Kang, Y., Zhou, J., & Yi, M. (2024). Harnessing the evolving CRISPR/Cas9 for precision oncology. Journal of Translational Medicine, 22(1), 749. https://doi.org/10.1186/s12967-024-05570-4
Liu, W., Li, L., Jiang, J., Wu, M., & Lin, P. (2021). Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics. Precision Clinical Medicine, 4(3), 179-191. https://doi.org/10.1093/pcmedi/pbab014
Maguire, M., & Delahunt, B. (2017). Doing a thematic analysis: A practical, step-by-step guide for learning and teaching scholars. All Ireland Journal of Higher Education, 9(3). https://doi.org/10.62707/aishej.v9i3.335
Mazhar, S. A., Anjum, R., Anwar, A. I., & Khan, A. A. (2021). Methods of data collection: A fundamental tool of research. Journal of Integrated Community Health, 10(1), 6-10. https://doi.org/10.24321/2319.9113.202101
National Cancer Institute (2022). CAR T cells: Engineering immune cells to treat cancer. [online] National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/research/car-t-cells
Nicol, D., Eckstein, L., Morrison, M., Sherkow, J. S., Otlowski, M., Whitton, T., ... & McWhirter, R. E. (2017). Key challenges in bringing CRISPR-mediated somatic cell therapy into the clinic. Genome Medicine, 9(1), 85. https://doi.org/10.1186/s13073-017-0475-4
Norsa’adah, B., Rampal, K. G., & Amin, R. M. (2021). Time taken for symptom recognition, first consultation, diagnosis and first definitive treatment and its associated factors among women with breast cancer. Asian Pacific Journal of Cancer Prevention: APJCP, 22(11), 3623. https://doi.org/10.31557/apjcp.2021.22.11.3623
Pederson, L. L., Vingilis, E., Wickens, C. M., Koval, J., & Mann, R. E. (2020). Use of secondary data analyses in research: Pros and Cons. Journal of Addiction Medicine and Therapeutic Science, 6(1), 058-060. https://doi.org/10.17352/2455-3484.000039
Polcz, S., & Lewis, A. (2016). CRISPR-Cas9 and the non-germline non-controversy. Journal of Law and the Biosciences, 3(2), 413-425. https://doi.org/10.1093/jlb/lsw016
Rasul, M. F., Hussen, B. M., Salihi, A., Ismael, B. S., Jalal, P. J., Zanichelli, A., ... & Taheri, M. (2022). Strategies to overcome the main challenges of the use of CRISPR/Cas9 as a replacement for cancer therapy. Molecular Cancer, 21(1), 1-30. https://doi.org/10.1186/s12943-021-01487-4
Resnik, D. (2015). What is ethics in research & why is it important? [Online] National institute of environmental health sciences. https://www.niehs.nih.gov/research/resources/bioethics/whatis
Samori, Z. & Rahman, F.A. (2024). Beyond Hopes, Beyond Cures: A Proposed Malaysian Regulatory Framework for Somatic Gene Therapy in Human. International Journal of Religion, 5(10), 4132–4155. https://doi.org/10.61707/btmq4740
Selvakumar, S. C., Preethi, K. A., Ross, K., Tusubira, D., Khan, M. W. A., Mani, P., ... & Sekar, D. (2022). CRISPR/Cas9 and next generation sequencing in the personalized treatment of Cancer. Molecular Cancer, 21(1), 83. https://doi.org/10.1186/s12943-022-01565-1
Uddin, F., Rudin, C. M., & Sen, T. (2020). CRISPR gene therapy: applications, limitations, and implications for the future. Frontiers in Oncology, 10, 1387. https://doi.org/10.3389/fonc.2020.01387
Wolyniak, M. J., Austin, S., Bloodworth III, L. F., Carter, D., Harrison, S. H., Hoage, T., ... & Challa, A. K. (2019). Integrating CRISPR-Cas9 technology into undergraduate courses: perspectives from a National Science Foundation (NSF) workshop for undergraduate faculty, June 2018. Journal of Microbiology & Biology Education, 20(1), 10-1128. https://doi.org/10.1128/jmbe.v20i1.1702
Wong, C. H., Li, D., Wang, N., Gruber, J., Lo, A. W., & Conti, R. M. (2023). The estimated annual financial impact of gene therapy in the United States. Gene Therapy, 30(10), 761-773. https://doi.org/10.1038/s41434-023-00419-9
Wong, L. P., Lai, L. L., See, M. H., Alias, H., Danaee, M., Ting, C. Y., & Tok, P. S. K. (2021). Psychological distress among cancer survivors during implementation of a nationwide Movement Control Order over the COVID-19 pandemic. Supportive Care in Cancer, 29(10), 6087-6097. https://doi.org/10.1007/s00520-021-06182-0
Xiaoshuai, L., Qiushi, W., & Rui, W. (2022). Advantages of CRISPR-Cas9 combined organoid model in the study of congenital nervous system malformations. Frontiers in Bioengineering and Biotechnology, 10, 932936. https://doi.org/10.3389/fbioe.2022.932936
Chan, Y. M., Ismail, M. Z. H., & Khaw, W. F. (2023). Factors influencing the prevalence of cervical cancer screening in Malaysia: a nationwide survey. BMC Women's Health, 23(1), 389. https://doi.org/10.1186/s12905-023-02553-3
Loh, E. Y. X., Ab Ghani, A., & Ahmad, R. (2023). Regulatory oversight of cell and gene therapy products in Malaysia. In Regulatory Aspects of Gene Therapy and Cell Therapy Products: A Global Perspective (pp. 181-195). Cham: Springer International Publishing. https://doi.org/10.1007/978-3-031-34567-8_10
Zhang, Y., Zhao, G., Ahmed, F. Y. H., Yi, T., Hu, S., Cai, T., & Liao, Q. (2020). In silico method in CRISPR/Cas system: an expedite and powerful booster. Frontiers in Oncology, 10, 584404. https://doi.org/10.3389/fonc.2020.584404
Su, Z. Y., Siak, P. Y., Leong, C. O., & Cheah, S. C. (2023). The role of Epstein–Barr virus in nasopharyngeal carcinoma. Frontiers in Microbiology, 14, 1116143. https://doi.org/10.3389/fmicb.2023.1116143
Park, H., Yu, S. and Koo, T. (2025). Gene editing in cancer therapy: Overcoming drug resistance and enhancing precision medicine. Cancer Gene Therapy, 32(9), 1451–1462. https://doi.org/10.1038/s41417-025-00567-x
Tang, S., Chen, X., Tong, X., & Zhu, L. (2025). Overcoming the delivery challenges in CRISPR/Cas9 gene editing for effective cancer treatment: A review of delivery systems. International Journal of Medical Sciences, 22(14), 3625. https://doi.org/10.7150/medsci.3625
Rauf, M. A., Rao, A., Sivasoorian, S. S., & Iyer, A. K. (2025). Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment: A comprehensive review. Cells, 14(15), 1136. https://doi.org/10.3390/cells14151136
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Malaysian Journal of Medical Research (MJMR)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
